Hong Kong’s Aprinoia Therapeutics to go public via SPAC merger

Aprinoia Therapeutics, a clinical-stage neuroscience biotech company, has agreed to go public in the US through a business combination with a publicly-traded special purpose acquisition company (SPAC) Ross Acquisition Corp II.

In an announcement, Aprinoia said the combination will result in a company called Aprinoia Therapeutics Holdings Ltd, with an enterprise value of as much as roughly $320 million.